Targeting p-MYH9 (Ser1943) and USP22, CX-4945 and S02, respectively, can abolish HIF-1α-induced LR, presenting a potentially effective therapeutic option for individuals with HCC and LR. Here, HIF1A is linked to hepatocellular carcinoma.